-
Elecsys® AFP-L3
Elecsys AFP-L3
AFP‑L3 is evaluated as a highly specific marker for HCC.
-
Elecsys® GALAD score
Elecsys® GALAD score
FDA grants Breakthrough Device Designation for Roche’s Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma
➾ The Elecsys GALAD score aims to support clinicians in diagnosing hepatocellular carcinoma by giving them more timely and accurate information to make earlier interventions
➾ When hepatocellular carcinoma is detected and managed at the very earliest, patient’s 5-year survival rates can increase to over 70%1
➾ Utilizing blood-based biomarkers, as part of the Elecsys GALAD score, is minimally invasive to patients
-
Elecsys® PIVKA-II
Elecsys® PIVKA-II
Elecsys® PIVKA-II is an immunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines
-
Elecsys® Troponin T-high sensitive
Elecsys® Troponin T-high sensitive
Enabling fast diagnosis of acute myocardial infarction.
Make a difference when every minute counts.
- HOME
- ABOUT US
- BRANDS
- Roche Diagnostics
- Roche Diabetes Care
- PIKDARE
- Sysmex
- Rodenstock Instruments
- bioMérieux
- Diagnostica Stago
- Dornier MedTech
- BioAir
- Bio-Rad
- THT Bio-Science
- Liofilchem
- Optika Microscopes
- Tuttnauer
- Steris
- Biosan
- Memmert
- Hamilton Medical
- Randox
- Lumenis
- BTL
- Hillrom
- Wärtsilä JOVYATLAS
- Geistlich Pharma AG
- Otopront
- NEWS
- TRAINING
- CONTACTS